Literature DB >> 32939741

The development of new method to differentiate between Dementia with Lewy bodies and Alzheimer's disease by cerebral perfusion SPECT-comparison to CIScore.

Gaku Honda1, Shigeki Nagamachi2, Masanari Nonokuma1, Koichi Takano1, Yasuo Kuwabara1, Kengo Yoshimitsu1, Hitoshi Iida3, Koji Ogomori3, Hiroaki Kawasaki3, Yoshio Tsuboi4.   

Abstract

PURPOSE: The Cingulate Island Sign score (CIScore) by rCBF SPECT is used in the differentiation between Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) but has some false-positive AD cases. To resolve the problem, we developed new differential diagnosing method incorporating occipital lobe and para-hippocampal rCBF.
MATERIALS AND METHODS: In 27 DLB and 31 AD cases undertaken Tc-99 m-ECD SPECT, we evaluated the mean Z score in the bilateral superior, middle, inferior occipital gyri, cuneus, amygdala, hippocampus, and para-hippocampus. One criterion of DLB was defined as the case with CIScore lower than 0.27. The other criteria were the cases of following either or both two conditions were satisfied. (1) The number of occipital gyri with mean Z score higher than 1 is three or more. (2) The number of hippocampal regions with mean Z score higher than 1 is one or less. We compared the differential diagnostic ability among these four criterions.
RESULTS: The diagnostic accuracy by CIscore was 69% and that of the occipital gyri analysis 84%, para-hippocampal regions analysis 76% and combined occipital gyri and para-hippocampal regions analysis 93%.
CONCLUSION: The new method by combined rCBF analysis of occipital gyri and para-hippocampal regions showed best diagnostic ability in differentiating DLB from AD.

Entities:  

Keywords:  Alzheimer’s disesase; DLB; Hippocampus; eZIS

Mesh:

Substances:

Year:  2020        PMID: 32939741     DOI: 10.1007/s11604-020-01041-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  2 in total

1.  Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer's disease from controls using brain perfusion SPECT.

Authors:  Etsuko Imabayashi; Hiroshi Matsuda; Takashi Asada; Takashi Ohnishi; Shigeki Sakamoto; Seigo Nakano; Tomio Inoue
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

2.  High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases.

Authors:  T Ohnishi; H Hoshi; S Nagamachi; S Jinnouchi; L G Flores; S Futami; K Watanabe
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.